Johnson & Johnson expands US availability of TECNIS PureSee IOL

Johnson & Johnson (NYSE: JNJ) announced the expanded U.S. rollout of its TECNIS PureSee IOL, an extended depth of focus intraocular lens designed for cataract surgery patients.

The TECNIS PureSee IOL is an FDA-approved presbyopia-correcting lens that addresses both cataract-related vision loss and presbyopia effects in a single procedure. The lens provides extended depth of focus, offering distance and intermediate vision with some near vision capability.

According to the company's press release, over 500,000 eyes worldwide have received the TECNIS PureSee IOL. Clinical data shows 97% of patients reported no bothersome visual disturbances and 97% would recommend the lens to others.

"With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option," said Erin Powers, President, Surgical Vision, North America, Johnson & Johnson.

The company notes that TECNIS PureSee IOL is the first FDA-approved extended depth of focus IOL with no warning on loss of contrast sensitivity. In clinical evaluation, the lens demonstrated contrast sensitivity comparable to an aspheric monofocal intraocular lens while maintaining distance visual acuity.

Johnson & Johnson launched a patient lifestyle quiz alongside the expanded availability to help individuals assess their vision needs before cataract surgery. The quiz aims to facilitate discussions between patients and eye care professionals about appropriate TECNIS IOL options.

The expansion coincides with Cataract Awareness Month. According to CDC data cited by the company, nearly 20% of Americans aged 40 and older live with cataracts, though only 5% have undergone cataract surgery.

You May Also Be Interested In

• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
• KeyCorp (KEY) files for 158.72M share offering by selling stockholders
• Murphy Oil announces oil discovery offshore Côte d'Ivoire